来自官方财务报表的收入、利润与现金流历史。
Jazz Pharmaceuticals plc 在美国、欧洲和国际上识别、开发和商业化药品。该公司提供 Xywav 来治疗猝倒或白天过度嗜睡 (EDS) 伴发作性睡病和特发性嗜睡症 (IH)； Epidiolex 用于治疗与 Lennox-Gastaut 综合征 (LGS)、Dravet 综合征 (DS) 或结节性硬化症 (TSC) 相关的癫痫发作； Rylaze 用于治疗急性淋巴细胞白血病或淋巴母细胞淋巴瘤； Enrylaze 治疗急性淋巴细胞白血病和淋巴母细胞淋巴瘤； Zepzelca 用于治疗在铂类化疗期间或之后疾病进展的转移性小细胞肺癌； Ziihera 治疗 HER2 阳性胆道癌； Modeyso 用于治疗携带 H3 K27M 突变的弥漫性中线胶质瘤； Defitelio 用于治疗严重的静脉闭塞性疾病。它还开发了处于 3 期试验的 Zanidatamab，用于治疗 HER2 阳性胃食管腺癌 (GEA) 和胆道癌 (BTC)； Dordaviprone 治疗 H3 K27M 突变型弥漫性胶质瘤；和 Vyxeos 用于治疗新诊断的治疗相关的急性髓系白血病。
机器翻译
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $4.6B | $4.3B | $4.1B | $3.8B | $3.7B | $3.1B | $2.4B | $2.2B | $1.9B | $1.6B | $1.5B | $1.3B | $1.2B | $872M | $586M | $272M | $174M | $128M | $68M | $65M | $45M |
| 毛利 | $3.9B | $3.8B | $3.6B | $3.4B | $3.1B | $2.7B | $2.2B | $2.0B | $1.8B | $1.5B | $1.4B | $1.2B | $1.1B | $770M | $508M | $258M | $160M | $119M | $54M | $56M | $38M |
| 毛利率% | 84.7% | 88.2% | 89.0% | 88.6% | 85.2% | 85.8% | 93.7% | 94.1% | 93.6% | 93.2% | 92.9% | 92.3% | 90.0% | 88.3% | 86.6% | 94.9% | 92.2% | 92.5% | 79.4% | 86.4% | 84.5% |
| 营业利润（EBIT） | — | $224M | $717M | $579M | ($66M) | $170M | $378M | $532M | $615M | $529M | $592M | $508M | $196M | $340M | $198M | $128M | $58M | $16M | ($170M) | ($139M) | ($78M) |
| 营业利润率% | — | 5.3% | 17.6% | 15.1% | -1.8% | 5.5% | 16.0% | 24.6% | 32.5% | 32.7% | 39.8% | 38.4% | 16.7% | 39.0% | 33.8% | 46.9% | 33.2% | 12.4% | -252.3% | -212.5% | -174.0% |
| 净利 | $940M | ($356M) | $560M | $415M | ($224M) | ($329M) | $239M | $523M | $447M | $488M | $397M | $330M | $58M | $216M | $289M | $125M | $33M | ($7M) | ($184M) | ($139M) | ($59M) |
| 净利润率 % | 20.4% | -8.3% | 13.8% | 10.8% | -6.1% | -10.6% | 10.1% | 24.2% | 23.6% | 30.1% | 26.7% | 24.9% | 5.0% | 24.8% | 49.2% | 45.9% | 18.9% | -5.3% | -273.0% | -212.6% | -132.4% |
| EBITDA | — | $108M | $1.5B | $1.4B | $1.5B | $1.0B | $1.0B | $1.0B | $933M | $779M | $754M | $666M | $584M | $454M | $310M | $134M | $54M | $25M | ($126M) | ($128M) | ($68M) |
| 每股收益（EPS） | $14.63 | $-5.84 | $8.49 | $5.76 | $-3.58 | $-5.51 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 | $3.51 | $4.79 | $2.67 | $0.83 | $-0.23 | $-7.19 | $-10.04 | $-4.41 |
| 已发行股数 (M) | — | 61M | 66M | 72M | 63M | 60M | 57M | 58M | 61M | 61M | 62M | 63M | 63M | 62M | 60M | 47M | 39M | 30M | 26M | 14M | 13M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 JAZZ 交互式查看器。 /companies/us/JAZZ
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms